About Us

JERRY RANDALL
Chairman

Mr. Randall is a qualified chartered accountant and previously served as the chief financial officer of Sinclair Pharmaceuticals plc which he joined in 2000 as part of a management buy-in team. Prior to this, Mr. Randall worked in corporate finance with Gambit Corporate Finance and had previously been involved in two other buy-ins. He acted as adviser to both private and quoted companies between 1993 and 2000, in both the capacity of nominated adviser and in practice with KPMG. During this period, he was involved in a number of flotations and transactions on the Official List, Unlisted Securities Market and the Alternative Investment Market, as well as raising private equity.

THOMAS CHRISTÉLY
Chief Executive Officer

Thomas Christély brings more than 20 years experience in corporate and business development and finance. He was instrumental in the merger of Silence Therapeutics AG (formerly Atugen AG) with Silence Therapeutics plc (formerly SR Pharma plc) and admission to the Alternative Investment Market of the London Stock Exchange. His track record includes concluding major collaborations with AstraZeneca, Pfizer, Dainippon Sumitomo and other pharma and biotech companies, multiple financing transactions as well as M&A, divestments and strategic restructurings. He has more than 19 years of management experience at board level thereof 14 years cross-border. Mr. Christély joined Atugen AG in 2001 as Chief Financial Officer and became Chief Operating Officer in 2002 before being appointed its Chief Executive Officer in 2006. Prior to joining Silence, he was Senior VP and CFO at OXO Chemie AG, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc. in San Francisco, where he stayed from 1997 until 2000. Mr. Christély was managing partner of the investment firm Löschen & Partner, Hamburg/Moscow, from 1992 to 1995 and worked in mergers & acquisitions at Enskilda Corporate Finance, London, from 1989 to 1992. After his studies in Hamburg and Geneva, he received degrees in Business Administration (equivalent to MBA) and Law from the University of Hamburg and was admitted as attorney-at-law. Thomas Christély is currently Chairman of the Supervisory Board of Müller-Spreer AG, Hamburg, and CEO of Silence Therapeutics AG.

ANNETTE CLANCY
Non-Executive Director

Ms. Clancy has had a distinguished career spanning 30 years with GlaxoSmithKline (GSK). She has 15 years experience in business development, leading GSK's global transactions and alliance management teams for the past three years, and during her tenure she and her team have been responsible for concluding a large number of research, development and commercial business collaborations on behalf of GSK. Prior to her role in business development, Ms. Clancy held a number of positions in clinical research, research and development project management and commercialization. Ms. Clancy has a BSc (Hons) in pharmacology from Bath University.

MAX HERRMANN
Chief Financial Officer and Company Secretary

Mr. Herrmann possesses more than 20 years of biotechnology and pharmaceutical industry experience having held key management positions with leading development stage companies, as well as several investment banks.  In these roles, he has been involved in raising more than $300M for biotechnology companies in the United States and Europe.  Most recently Mr. Herrmann served as CFO of Intercytex Group plc, a publicly traded company focused on the emerging area of regenerative medicine.  Before joining Intercytex, he spent over ten years as a sell-side equity analyst, most recently as managing director and head of European pharmaceutical and biotechnology research at ING.  He has also held the position of financial controller for US-based Onyx Pharmaceuticals Inc and currently serves on the boards of Regenerative Medicine Assets Limited.

Mr. Herrmann qualified as a Chartered Accountant with Arthur Andersen in 1993. He holds a degree in microbiology from the University of Kent.

DAVID MACK, Ph.D
Non-Executive Director

Dr. Mack is a director at Alta Partners where he led the investment in Angiosyn as a director and acting CEO (acquired by Pfizer in 2005). He joined Intradigm’s board in May 2006 and served on that board until the merger with Silence Therapeutics. He is currently on the board of directors of Aerie Pharmaceuticals, Ceregene and Proacta. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. He was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s.

Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science and Nature, and he is an inventor on 21 US patents. He was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology. Dr. Mack received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology. He holds a Bachelor of Arts in Molecular Biology from University of California, Berkeley.